SCHOLAR ROCK HOLDING CORPORATION Share-based Payment Arrangement, Accelerated Cost
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Share-based Payment Arrangement, Accelerated Cost of $600.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2021-03-09
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, accelerated cost for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, accelerated cost for the quarter ending 2019-09-30 was $600.00K, a 100.00% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, accelerated cost for the quarter ending 2018-12-31 was $900.00K.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, accelerated cost for the quarter ending 2018-09-30 was $300.00K.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, accelerated cost for fiscal 2019 was $600.00K, a 50.00% decline from fiscal 2018.
- SCHOLAR ROCK HOLDING CORPORATION share-based payment arrangement, accelerated cost for fiscal 2018 was $1.20M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month | Share-based Payment Arrangement, Accelerated Cost 9 month as first filed | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $600.00K derived: sum of 2 quarters · filed 2021-03-09 | $600.00K 10-K · filed 2021-03-09 | ||
| 2019-09-30 | $600.00K 10-Q · filed 2020-11-09 | $600.00K 10-Q · filed 2020-11-09 | $100.00K 10-Q · filed 2019-11-12 | ||
| 2018-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $1.20M derived: sum of 2 quarters · filed 2019-11-12 | $1.20M 10-K · filed 2019-03-19 | ||
| 2018-09-30 | $300.00K 10-Q · filed 2019-11-12 | $300.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |